nav1.9

Aneratrigine hydrochloride is a sodium channel protein type 9 subunit blocker that may be used for the prevention or treatment of sodium channel blocker-related diseases.

Anti-SCN11a/Nav1.9 Antibody is a humanized monoclonal antibody that binds specifically to the extracellular domain of Nav1.9 (e.g., α subunit) with high affinity and blocks its mediated ion currents, serving as an important pharmacological tool for researching chronic pain, inflammatory pain, and hereditary pain disorders.

E0199 is an innovative and potent KV7/NaV dual-target modulator that activates KV7 potassium channels, including KV7.2/7.3 (EC50 = 12.78 nM), KV7.2 (EC50 = 0.50 μM), and KV7.5 (EC50 = 27.14 nM), while inhibiting NaV1.7 (IC50 = 0.52 μM), NaV1.8 (IC50 = 0.24 μM), and NaV1.9 (IC50 = 0.16 μM) sodium channels. In a mouse model of chronic constriction injury (CCI) to the sciatic nerve, E0199 demonstrated potent analgesic effects without significant impact on cardiac and skeletal muscle ion channels. E0199 is applicable in studies related to neuropathic pain (NP).

Heteropodatoxin-1 (HpTx1), a spider peptide toxin, inhibits Kv4.2 and Nav1.7 currents while activating Nav1.9 channels, with no effect on Nav1.8 channels [1].

LTGO-33 is a species-specific inhibitor of the voltage-gated sodium channel NaV1.8, inhibiting NaV1.8, NaV1.1-NaV1.7, and NaV1.9.LTGO-33 inhibits wild-type and multiple NaV1.8 variants associated with human pain disorders and can be used for the study of pain.hBChE-IN-2 is a low affinity Nurr1 agonist.